株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

インドの無侵襲的出生前検査(NIPT)の新規市場

Emerging Indian NIPT Market

発行 RNCOS E-Services Pvt. Ltd. 商品コード 296319
出版日 ページ情報 英文 110 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。
Back to Top
インドの無侵襲的出生前検査(NIPT)の新規市場 Emerging Indian NIPT Market
出版日: 2014年02月01日 ページ情報: 英文 110 Pages
概要

無侵襲的出生前検査(NIPT)は新しい出生前検査技術として、米国から欧州・アジア太平洋地域へと普及しています。中国・日本・オーストラリアなどの市場も急速に成長していますが、どの企業もインドにはまだ進出しておらず、同国の市場はまだ未開拓のままとなっています。将来的には、体外受精(IVF)の普及や、不妊治療のためのメディカルツーリズム、病理解析サービス・ネットワークの急速な拡大といった要素を受けて、インドでもNIPTが急速に普及していくものと思われます。

当レポートでは、インドにおける無侵襲的出生前検査(NIPT)市場の将来展望について分析し、NIPT技術の概要や種類、インド国内の経済・医療インフラ、同国の潜在的な市場規模・機会、規制環境、主なNIPT企業および病理解析サービス・体外受精サービス企業のプロファイルといった情報をお届けいたします。

第1章 アナリストの見解

第2章 分析手法

第3章 無侵襲的出生前検査(NIPT)の概要

  • MaterniT21 PLUS
  • Verifi
  • Panorama
  • Harmony
  • NIFTY(無侵襲胎児トリソミー)
  • Bambni

第4章 胎児のダウン症候群リスクと母親の年齢との関係性

第5章 インドのマクロ経済的要因、医療インフラ、人口構造

  • 国のプロファイル
  • 医療費支出額
  • 病院・サブセンター・プライマリヘルスケア(PHC)・地域医療センター(CHC)
  • 病理検査所
  • 体外受精クリニック
  • 人口

第6章 インドのNIPT:潜在的市場

  • 潜在的な顧客ベース
  • 外資系企業の市場参入戦略
    • インド国内に研究所を設置すべきか、それとも本国にサンプルを送付させるか?
    • 顧客対応の窓口(現地の提携先)となるのは誰か?
    • どうやって消費者を惹きつけるのか?
  • インドの産婦人科におけるNIPTの見通し:調査結果
    • 調査回答者の特徴
    • 出生前検査に関する現在の課題:インド市場のシナリオ
    • NIPTに対する認知水準
    • 産婦人科医の見解

第7章 規制シナリオ

第8章 主なNIPT企業

  • Ariosa Diagnostics
    • 事業概要
    • 競争上の強み・弱み
  • Sequenom
  • Verinata
  • Natera
  • BGI
  • Berry Genomics

第9章 インドの病理検査サービス市場の主要企業

  • SRL Diagnostics
  • Dr. Lal Pathlabs
  • Metropolis India
  • Thyrocare
  • Quest Diagnostics

第10章 インドの主な体外受精(IVF)クリニック

  • Bourn Hall Clinic
  • Southend Fertility and IVF Centre
  • Morpheus IVF Fertility Center
  • Bloom Fertility Center
  • Manipal Ankur
  • Cloudnine Fertility
  • Nova IVI Fertility
  • Srushti Test Tube Baby Center

図表一覧

目次

Our dedicated team of industry experts intensively monitored and analyzed all the emerging trends in the global molecular diagnostics market. According to their assessment, NIPT has fast emerged as the quickest growing segment. Players, who are actively establishing their base in the US, are also fanning out to the EU and APAC regions. Interestingly, despite catching up on the Chinese, Japanese and Australian markets, players are yet to enter the Indian market. This report has been made to act as a pristine source of business intelligence for players looking to enter the highly lucrative Indian NIPT market.

In their latest research study "Emerging Indian NIPT Market", RNCOS analysts have identified various factors to showcase the immense potential of the Indian NIPT market. These factors like the number of births by the age of mother, rural and urban split of such births; affordability for NIPT; and regulatory scenario have been prudently analyzed to reflect a clear picture of the immense possibilities in the Indian NIPT market.

The report provides a depiction of macro-economic factors and healthcare infrastructure relevant in the context of NIPT. Our study reveals that in India, NIPT will be eagerly adopted by the booming IVF clinics that are witnessing a huge surge in fertility tourism. Also, India is home to a rapidly expanding network of pathology labs. In order to differentiate themselves from competition, organized players in the Indian diagnostic services market are looking forward to adopting new tests.

RNCOS has used its expertise in the Indian IVF and diagnostic services market to provide a relevant snapshot of these markets in the report. Leading players in both markets have been profiled with details about their infrastructure and analysis of their strengths and weaknesses, which will prove to be of value to NIPT players looking for partnering opportunities in India. Besides, to offer a glimpse of NIPT players in the global market to the diagnostic services players looking forward for partnerships and collaborations, detailed profiling of NIPT players, including the description of their test offering along with strengths and weaknesses analysis of their NIPT business has been provided.

The report also includes the findings from another RNCOS survey namely "Gynecologists survey to assess the potential for NIPT in India." The survey was done between September-December 2012 with around 100 leading gynecologists in India. The key findings reveal that currently the awareness level of NIPT is very low in India. But when made aware about the benefits of NIPT, all gynecologists agreed that if launched tactfully, such a technology would have a tremendous scope to revolutionize the prenatal diagnosis scenario in India.

Insights from analysts will prove to be invaluable for NIPT players looking forward to entering the Indian market. Analysts have prudently assessed various factors to critically evaluate different possible business models and device apt marketing strategies. The report is a must buy for all players interested in the Indian NIPT market.

Table of Contents

1. Analyst View

2. Research Methodology

3. Introduction to Non-Invasive Prenatal Testing (NIPT)

  • 3.1 MaterniT21 PLUS
  • 3.2 Verifi
  • 3.3 Panorama
  • 3.4 Harmony
  • 3.5 NIFTY
  • 3.6 Bambni

4. Association of Down's syndrome Risk to Fetus with Mother's Age

5. India: Macro-Economic Factors, Healthcare Infrastructure and Population Demographics

  • 5.1 Country Profile
  • 5.2 Healthcare Spending
  • 5.3 Hospitals, Sub-Centres, PHCs, CHCs
  • 5.4 Pathology Labs
  • 5.5 In-Vitro Fertilization Clinics
  • 5.6 Population

6. NIPT India: Market Potential

  • 6.1 Potential Customer Base
  • 6.2 Market Entry Strategy for Foreign Players
    • 6.2.1 Whether one should Setup a Lab in India or Send Samples to Base Country?
    • 6.2.2 Who should be Company's Face to Customer?
    • 6.2.3 How should the Consumer be Allured?
  • 6.3 Gynecologists and Obstetricians Outlook on NIPT in India: Survey Findings
    • 6.3.1 Respondent Demographics
    • 6.3.2 Current Challenges of Prenatal Testing: Indian Scenario
    • 6.3.3 Awareness Level for NIPT
    • 6.3.4 Gynecologists and Obstetricians Opinion

7. Regulatory Scenario

8. Key NIPT Players

  • 8.1 Ariosa Diagnostics
    • 8.1.1 Business Overview
    • 8.1.2 Strengths and Weaknesses
  • 8.2 Sequenom
    • 8.2.1 Business Overview
    • 8.2.2 Strengths and Weaknesses
  • 8.3 Verinata
    • 8.3.1 Business Overview
    • 8.3.2 Strengths and Weaknesses
  • 8.4 Natera
    • 8.4.1 Business Overview
    • 8.4.2 Strengths and Weaknesses
  • 8.5 BGI
    • 8.5.1 Business Overview
    • 8.5.2 Strengths and Weaknesses
  • 8.6 Berry Genomics
    • 8.6.1 Business Overview
    • 8.6.2 Strengths and Weaknesses

9. Key Players in Indian Pathological Services Market

  • 9.1 SRL Diagnostics
    • 9.1.1 Business Overview
    • 9.1.2 Strengths and Weaknesses
  • 9.2 Dr. Lal Pathlabs
    • 9.2.1 Business Overview
    • 9.2.2 Strengths and Weaknesses
  • 9.3 Metropolis India
    • 9.3.1 Business Overview
    • 9.3.2 Strengths and Weaknesses
  • 9.4 Thyrocare
    • 9.4.1 Business Overview
    • 9.4.2 Strengths and Weaknesses
  • 9.5 Quest Diagnostics
    • 9.5.1 Business Overview
    • 9.5.2 Strengths and Weaknesses

10. Key IVF Clinics in India

  • 10.1 Bourn Hall Clinic
    • 10.1.1 Business Overview
    • 10.1.2 Strengths and Weaknesses
  • 10.2 Southend Fertility and IVF Centre
    • 10.2.1 Business Overview
    • 10.2.2 Strengths and Weaknesses
  • 10.3 Morpheus IVF Fertility Center
    • 10.3.1 Business Overview
    • 10.3.2 Strengths and Weaknesses
  • 10.4 Bloom Fertility Center
    • 10.4.1 Business Overview
    • 10.4.2 Strengths and Weaknesses
  • 10.5 Manipal Ankur
    • 10.5.1 Business Overview
    • 10.5.2 Strengths and Weaknesses
  • 10.6 Cloudnine Fertility
    • 10.6.1 Business Overview
    • 10.6.2 Strengths and Weaknesses
  • 10.7 Nova IVI Fertility
    • 10.7.1 Business Overview
    • 10.7.2 Strengths and Weaknesses
  • 10.8 Srushti Test Tube Baby Center
    • 10.8.1 Business Overview
    • 10.8.2 Strengths and Weaknesses

List of Figures

  • Figure 3-1: MaterniT21 PLUS Test Validation Results
  • Figure 3-2: Verifi Test Validation Results
  • Figure 3-3: Panorma Test Validation Results
  • Figure 3-4: Harmony Test Validation Results
  • Figure 3-5: NIFTY Test - Summary of Phase I Clinical Trial
  • Figure 3-6: NIFTY Test - Summary of Phase II Clinical Trial
  • Figure 4-1: Risk of Down's syndrome with Rise in Maternal Age
  • Figure 5-1: Healthcare Spending (US$ per head), 2013-2018
  • Figure 5-2: Consumer Healthcare Spending (Billion US$), 2013-2018
  • Figure 5-3: Share of Diagnostic Services in Total Healthcare Expenditure (2013)
  • Figure 5-4: Breakup of Public Hospitals by Urban and Rural India (%), 2012
  • Figure 5-5: Breakup of Public Hospitals Beds by Urban and Rural India (%), 2012
  • Figure 5-6: Forecast for Share of Organized Pathology Services Market (2018)
  • Figure 5-7: IVF Clinics Presence by Number of Cycles Performed (%), 2013
  • Figure 5-8: IVF Clinics Presence by Number of Cycles Performed and Structure (%), 2013
  • Figure 5- 9: Population (Million), 2013-2018
  • Figure 5-10: Middle Class Population (Million), 2013-2018
  • Figure 6-1: India - Number of Births (Million), 2013-2018
  • Figure 6-2: India - Number of Births by Mother's Risk of Down's Syndrome (%), 2013
  • Figure 6-3: Number of Households Earning more than US$ 10,000 Per Annum (Million) 2013-2018
  • Figure 6-4: Factors Influencing the Indian NIPT Consumer
  • Figure 6-5: Respondent Gynecologists by Tier
  • Figure 6-6: Respondent Gynecologists by Region
  • Figure 6-7: Recommendations for Amniocentesis/CVS per Year
  • Figure 6-8: Challenges with Invasive Prenatal Tests
  • Figure 6-9: Are you Aware of DNA sequencing Based Non-Invasive Prenatal Tests (NIPT)?
  • Figure 6-10: Are you Aware of Technology used in NIPT?
  • Figure 6-11: What NIPT Players are you Aware of?
  • Figure 6-12: Respondents Who are Interested in NIPT Post Being Made Aware about its Advantages
  • Figure 6-13: Age-Based Profile of Patient to Whom Respondents will Recommend NIPT
  • Figure 6-14: Respondents Who Recommend Integration of NIPT with Regular Maternal Screens

List of Tables

  • Table 3-1: Comparison of Features of Key NIPT Tests in APAC NIPT Market
  • Table 3-2: Bambni Test - Summary of Phase I Clinical Trial
  • Table 3-3: Bambni Test - Summary of Phase II Clinical Trial
  • Table 5-1: Key Economic Indicators (2012)
  • Table 5-2: State-wise Breakup of Government Hospitals and Hospital Beds (2012)
  • Table 5-3: State-wise Breakup of Sub Centres, PHCs and CHCs (2012)
  • Table 5-4: Population Break-up by Age-Group (Million), 2013-2018
  • Table 6-1: India - Number of Births by Age of Mother and Region of Birth (2013)
  • Table 6-2: India - NIPT Potential Market (Million US$) and Potential Customers (2013)
  • Table 10-1: Presence of Bourn Hall Clinic
  • Table 10-2: Presence of Southend Fertility and IVF Center
  • Table 10-3: Presence of Morpheus IVF Fertility Center
  • Table 10-4: Presence of Bloom Fertility Center
  • Table 10-5: Presence of Manipal Ankur
  • Table 10-6: Presence of Cloudnine Fertility
  • Table 10-7: Presence of Nova IVI Fertility
  • Table 10-8: Presence of Srushti Test Tube Centre
Back to Top